Clinical Trial Update: Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene [Phase 2]

View source ↗

Summary

Phase II trial assessing whether radiographic response to the EGFR inhibitor gefitinib correlates with EGFR mutations in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (Gefitinib) (Gefitinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lung Cancer, Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-01-22